Skye Bioscience, Inc. Operating Income Loss

• Skye Bioscience, Inc. showed a decrease of -92.6% in Operating Income Loss from 2024 to 2025.
• This data is from Skye Bioscience, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
• XBRL data for this metric is available from 2012 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 15 years of available data (2012 to 2025), Skye Bioscience, Inc.'s Operating Income Loss has declined by 1,412,865.7%.
• Historical annual values: Fiscal year 2025: -$58.16 million | Fiscal year 2024: -$30.19 million | Fiscal year 2023: -$34.74 million | Fiscal year 2022: -$18.31 million | Fiscal year 2021: -$7.85 million | Fiscal year 2020: -$6.29 million | Fiscal year 2019: -$6.63 million | Fiscal year 2018: -$4.69 million | Fiscal year 2017: -$3.86 million | Fiscal year 2016: -$4.47 million | Fiscal year 2015: -$4.32 million | Fiscal year 2014: -$2.73 million | Fiscal year 2013: -$120.4 thousand | Fiscal year 2013: -$7.2 thousand | Fiscal year 2012: $4.1 thousand.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026